UBS raises Biogen target to $270 from $240, maintains Buy

On Oct. 9, UBS analyst Michael Yee raised the price target to $270 from $240 and maintained Buy. BIIB closed at $225.71, up 3.33% that day; the source does not attribute the move to the analyst action.